Viabilidade t?cnica e impacto econ?mico da erradica??o de Streptococcus agalactiae em rebanhos bovinos

• Main Author: Carneiro, Alziro Vasconcelos
• Other Authors: Fonseca, Adevair Henrique da
• Format: Others
• Language: Portuguese
• Published: Universidade Federal Rural do Rio de Janeiro 2016
• Subjects: mastite bovina; terapia de ataque; an?lise custo-benef?cio; bovine mastitis; blitz therapy; cost-benefit analysis; CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA::MEDICINA VETERINARIA PREVENTIVA::EPIDEMIOLOGIA ANIMAL
• Online Access: https://tede.ufrrj.br/jspui/handle/tede/845

Made available in DSpace on 2016-04-28T20:16:31Z (GMT). No. of bitstreams: 1 2006-Alziro Vasconcelos Carneiro.pdf: 455403 bytes, checksum: 96b519d909bc30f30ddc42546978acfb (MD5) Previous issue date: 2006-07-31 === There are several pathogens causing bovine mastitis, but only Streptococcus agalactiae is feasible to be eradicated from a herd. Two herd data ( A and B ) were used to evaluate the economic and technical viability of the eradication of this pathogen, based on this pathogen attack program. It was used a 24 month period data from production; somatic cells count (SCC), clinical mastitis and expenditures. A cost-benefit analysis was carried out through mathematical models. It was identified 16 infected cows with S. agalactiae in herd A , and in herd B , there were 42, from which 31 associated with Staphylococcus aureus. The therapy effectiveness in eliminating S. agalactiae was about 100% in both herds. However, 18 cows kept the infection of S. aureus after the therapy (42% of effectiveness). The number of cases and cows with mastitis decrease was about 18% and 21%, respectively. For herd B it was found a SCC growing tendency on infected group and on total milk, 12 months before the therapy (980x10P 3 P and 968x10P 3 P cells/ml averages, respectively) and stabilization after treatment (577x10P 3 P cells/ml and 563x10P 3 P cells/ml averages, respectively). Treatment cost was about R$ 175.95 per cow considering the following higher cost items: laboratory exams (39%); milk discard (31%); veterinary medicaments and labor for additional operations (20%); and veterinary fees (10%). Payment due to quality and to the decrease in clinical mastitis cases represented about 55% e 34% of total benefit. However, it was not found significant milk production increase for treatment program (p>0.05), in treated group, nor in herd B . It was estimated about 11.67; 6.45 and 2.61 monetary unit return for each unit invested. Prophylactic procedures were important to eradicate and maintain the herd free from S. agalactiae, they have also contributed for lower incidence of clinical mastitis, decreasing SCC and discard/precocious mortality, so its adoption is recommended. Considering Brazilian requirements relative to somatic cells and milk total bacterial as well as S. agalactiae role in increasing these parameters, it is suggested an eradication program of this pathogen, which may help farmers to maintain production under standard requirements, as well as the consumers reducing risk and Government income loss due to taxes collection. === Entre os v?rios pat?genos causadores de mastite, o ?nico que pode ser erradicado do rebanho ? Streptococcus agalactiae. Dados de dois rebanhos, 'A' e 'B', foram utilizados para avaliar a viabilidade t?cnica e econ?mica de um programa de erradica??o deste pat?geno. Foram utilizados dados de produ??o, contagem de c?lulas som?ticas (CCS), mastite cl?nica e financeiros, de 24 meses. An?lise custo/benef?cio foi realizada com aux?lio de modelos matem?ticos. Identificaram-se 16 vacas infectadas com S. agalactiae no rebanho 'A' e 42 no rebanho 'B', sendo que destas ?ltimas, 31 apresentaram infec??o associada com Staphylococcus aureus. A efic?cia da terapia de ataque foi de 100% nos dois rebanhos. Entretanto, 18 vacas no rebanho B mantiveram a infec??o por S. aureus ap?s a terapia (42% de efic?cia). No rebanho 'B', a redu??o do n?mero de casos e de vacas com mastite cl?nica foi de 18 e 21%, respectivamente. A CCS apresentou tend?ncia crescente no grupo infectado e no leite total, nos 12 meses antecedentes ? terapia, com as m?dias de 980x103 e 968x103 c?l/ml, respectivamente. Ap?s o tratamento, as m?dias estabilizaram-se em 541x103 e 563x103 c?l/ml, respectivamente. O custo do tratamento foi de R$ 175,95 por vaca/tratada, sendo 39% deste com exames laboratoriais, 31% descarte de leite, 20% medicamentos e m?o-de-obra devido a opera??es adicionais e 10% honor?rios do m?dico veterin?rio. O pagamento por qualidade e a redu??o dos custos com a mastite cl?nica representaram 55% e 34% do benef?cio. Aumento significativo n?o foi observado (p>0,05) na produ??o m?dia de leite dos grupos tratados e do rebanho 'B'. Estimaram-se retornos de 11,67, 6,45 e 2,63 unidades monet?rias para cada unidade investida no programa de erradica??o de S. agalactiae. As medidas terap?uticas e profil?ticas foram eficazes para erradicar e manter o rebanho livre de S. agalactiae, al?m de contribu?rem para reduzir a CCS do leite, a incid?ncia de mastite cl?nica, o descarte/mortalidade precoce e proporcionou ganhos em programa de pagamento por qualidade, sendo sua ado??o recomend?vel. Considerando as exig?ncias brasileiras com rela??o ao limite de c?lulas som?ticas e de bact?rias totais no leite e o papel de S. agalactiae no aumento desses par?metros, o programa de erradica??o deste pat?geno pode significar a perman?ncia do produtor na atividade formal, al?m de reduzir risco para os consumidores e perdas de receitas do Governo com recolhimento de impostos.